Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine k...

Full description

Bibliographic Details
Main Authors: Ting-Ting Yang, Wei-Hao Chen, Yan-Min Zhao, Hua-Rui Fu, He Huang, Ji-Min Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
hematopoietic stem cell transplantation
EBV-negative
posttransplant lymphoproliferative disorder
lymphoma
zanubrutinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.672052/full
id doaj-8db065df053c43e8b368d61e93b01285
record_format Article
spelling doaj-8db065df053c43e8b368d61e93b012852021-04-29T10:42:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.672052672052Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case ReportTing-Ting Yang0Ting-Ting Yang1Ting-Ting Yang2Wei-Hao Chen3Wei-Hao Chen4Wei-Hao Chen5Yan-Min Zhao6Yan-Min Zhao7Yan-Min Zhao8Hua-Rui Fu9Hua-Rui Fu10Hua-Rui Fu11He Huang12He Huang13He Huang14Ji-Min Shi15Ji-Min Shi16Ji-Min Shi17Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, ChinaPosttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.https://www.frontiersin.org/articles/10.3389/fonc.2021.672052/fullhematopoietic stem cell transplantationEBV-negativeposttransplant lymphoproliferative disorderlymphomazanubrutinib
collection DOAJ
language English
format Article
sources DOAJ
author Ting-Ting Yang
Ting-Ting Yang
Ting-Ting Yang
Wei-Hao Chen
Wei-Hao Chen
Wei-Hao Chen
Yan-Min Zhao
Yan-Min Zhao
Yan-Min Zhao
Hua-Rui Fu
Hua-Rui Fu
Hua-Rui Fu
He Huang
He Huang
He Huang
Ji-Min Shi
Ji-Min Shi
Ji-Min Shi
spellingShingle Ting-Ting Yang
Ting-Ting Yang
Ting-Ting Yang
Wei-Hao Chen
Wei-Hao Chen
Wei-Hao Chen
Yan-Min Zhao
Yan-Min Zhao
Yan-Min Zhao
Hua-Rui Fu
Hua-Rui Fu
Hua-Rui Fu
He Huang
He Huang
He Huang
Ji-Min Shi
Ji-Min Shi
Ji-Min Shi
Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
Frontiers in Oncology
hematopoietic stem cell transplantation
EBV-negative
posttransplant lymphoproliferative disorder
lymphoma
zanubrutinib
author_facet Ting-Ting Yang
Ting-Ting Yang
Ting-Ting Yang
Wei-Hao Chen
Wei-Hao Chen
Wei-Hao Chen
Yan-Min Zhao
Yan-Min Zhao
Yan-Min Zhao
Hua-Rui Fu
Hua-Rui Fu
Hua-Rui Fu
He Huang
He Huang
He Huang
Ji-Min Shi
Ji-Min Shi
Ji-Min Shi
author_sort Ting-Ting Yang
title Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_short Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_full Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_fullStr Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_full_unstemmed Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_sort zanubrutinib treatment of central nervous system posttransplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case report
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-04-01
description Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.
topic hematopoietic stem cell transplantation
EBV-negative
posttransplant lymphoproliferative disorder
lymphoma
zanubrutinib
url https://www.frontiersin.org/articles/10.3389/fonc.2021.672052/full
work_keys_str_mv AT tingtingyang zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT tingtingyang zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT tingtingyang zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT weihaochen zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT weihaochen zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT weihaochen zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT yanminzhao zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT yanminzhao zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT yanminzhao zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT huaruifu zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT huaruifu zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT huaruifu zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT hehuang zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT hehuang zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT hehuang zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT jiminshi zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT jiminshi zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT jiminshi zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
_version_ 1721501297741398016

Similar Items